NRx Pharmaceuticals just dropped a major Q1 2026 update — and the catalyst stack is loaded. ????????
Full update : https://www.stockonhighalert.com/post/nrxp-nr...ate-update
FDA decision for KETAFREE™ ANDA expected Q3 2026
Commercial ketamine manufacturing initiated at 1M dose/month scale
FDA accepted IND for NRX-101 + robotic TMS study
First revenue generated from 5 interventional psychiatry clinics
HOPE Therapeutics clinic footprint expanding
Pending Geneuro asset acquisition adds Phase 2 neuro/immunology portfolio
Q1 net loss improved to $1.4M vs. $5.5M YoY
$NRXP is positioning itself at the intersection of ketamine, mental health, PTSD, depression, and FDA-driven biotech catalysts. ????????